[SCHEDULE 13G/A] Cidara Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Adage Capital Management and two principals report a passive 4.97% stake in Cidara Therapeutics (CDTX), holding 1,100,000 shares in shared voting and dispositive power. The filings identify Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as the reporting persons and state the position is held in the ordinary course of business and not to influence control. The percentage is calculated on a pro forma share count of 22,117,550 shares, which combines 12,969,823 outstanding shares as of May 5, 2025 and 9,147,727 shares issued under a June 25, 2025 prospectus after full exercise of the over-allotment.

The report shows 0 sole voting/dispositive power and 1,100,000 shares of shared voting/dispositive power, placing the holding under the 5% reporting threshold for greater-than-5% ownership.

Positive

• Clear disclosure of a 1,100,000-share position representing 4.97% of CDTX on a pro forma basis
• Filing identifies reporting persons (Adage Capital Management, Robert Atchinson, Phillip Gross) and their business address
• Percentage calculation transparency showing the pro forma share count (22,117,550) that includes the recent offering

Negative

• Position is under 5%, limiting the ability to effect corporate control or materially influence governance
• No sole voting or dispositive power reported (0 sole power), indicating limited unilateral authority over shares
• Filing indicates passive intent, stating shares were not acquired to change or influence control

Insights

Securities Analyst

TL;DR: Adage discloses a passive sub-5% stake (1.1M shares), limiting near-term governance influence.

The Schedule 13G/A shows Adage and two named principals collectively beneficially own 1,100,000 shares, representing 4.97% of CDTX on a pro forma basis. The filing is presented as passive: no sole voting or dispositive power is claimed and the certification affirms the position was acquired in the ordinary course and not to change control. For investors, this is a material disclosure of a meaningful institutional holding but it does not signal an activist intent or imminent governance change.

Corporate Governance Expert

TL;DR: Reported ownership is significant for disclosure but does not indicate control or a challenge to management.

The report clarifies that the stake is shared voting/dispositive power only, with 0 sole power reported. The filing cites a pro forma share base of 22,117,550 shares reflecting a recent equity issuance, which is important context for the sub-5% percentage. Because the filing is a Schedule 13G/A and includes the ordinary-course certification, the posture is passive under SEC rules; shareholders and boards should view this as a disclosure of concentration rather than an activist approach.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cidara Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

171757206

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Adage Capital Management, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,100,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,100,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,100,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.97 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Robert Atchinson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,100,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,100,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,100,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.97 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Phillip Gross

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,100,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,100,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,100,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.97 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cidara Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Cidara Therapeutics, Inc., a Delaware corporation (the "Company") directly held by ACP; (ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and (iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
(c)	Citizenship: ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 171757206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 22,117,550 shares of Common Stock, which is the sum of (i) 12,969,823 shares of Common Stock outstanding as of May 5, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025; and (ii) 9,147,727 shares of Common Stock issued and sold by the Company pursuant to the Company's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 25, 2025, as described therein and in the Company's press release dated as of June 26, 2025, after giving effect to the completion of the offering and full exercise of the underwriters' over-allotment option, all as described therein.
(b)	Percent of class: 4.97%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Adage Capital Management, L.P.

Signature:	/s/ Robert Atchinson
Name/Title:	By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:	08/12/2025

Robert Atchinson

Signature:	/s/ Robert Atchinson
Name/Title:	Robert Atchinson, individually
Date:	08/12/2025

Phillip Gross

Signature:	/s/ Phillip Gross
Name/Title:	Phillip Gross, individually
Date:	08/12/2025

FAQ

How many CDTX shares does Adage Capital report owning?

The filing reports Adage Capital and the named individuals beneficially own 1,100,000 shares of CDTX.

What percentage of Cidara Therapeutics (CDTX) does the 1,100,000 shares represent?

The reported position represents 4.97% of CDTX on a pro forma share count of 22,117,550 shares.

Does Adage report sole voting or dispositive power over the CDTX shares?

No. The filing reports 0 shares with sole voting power or sole dispositive power and 1,100,000 shares with shared voting and dispositive power.

Is the Schedule 13G/A filing passive or activist?

The filing is presented as a Schedule 13G/A with a certification stating the shares were acquired in the ordinary course and not to change or influence control, indicating a passive position.

What pro forma share count was used to calculate the ownership percentage?

The percentage is calculated using a pro forma total of 22,117,550 shares, combining 12,969,823 outstanding shares as of May 5, 2025 and 9,147,727 shares issued pursuant to a June 25, 2025 prospectus after full exercise of the over-allotment.